Australian biotech market watch 09/10/09

The All Ordinaries has shed some of the gains made over the past couple of days to level out around 4,753 as of 1pm this afternoon.

However, the S&P/ASX 200 Health Care index has underperformed the rest of the market, dropping 176 points to 8,428.

A large portion of that drop can be attributed to a 2.5% fall in CSL (ASX:CSL) to $31.89, closely followed by Primary Health Care (ASX:PRY), which also shed 2.5%, down to $6.34, as well as Cochlear (ASX:COH), which lost $1.42, or 2.1%, to $64.84.

Ansell (ASX:ANN), which has had a good run this week, plateaued around $10.59, down 15c from yesterday's close.

Ramsay Health Care (ASX:RHC) saw an early rally, but has since dropped back 8c below yesterday's close to sit at $10.64.

On the up side, ResMed (ASX:RMD) experienced a 1.8% lift to $5.06, and Blackmores (ASX:BKL) hit a 12 month high of $21.27.